

HR 3160

Pharmaceutical Research Transparency Act of 2023

Congress: 118 (2023–2025, Ended)

Chamber: House

Policy Area: Health

Introduced: May 9, 2023

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (May 12, 2023)

Official Text: <https://www.congress.gov/bill/118th-congress/house-bill/3160>

Sponsor

Name: Rep. Raskin, Jamie [D-MD-8]

Party: Democratic • **State:** MD • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Slotkin, Elissa [D-MI-7]	D · MI		Jun 12, 2023

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	May 12, 2023
Financial Services Committee	House	Referred To	May 9, 2023

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
118 S 1476	Identical bill	May 9, 2023: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Pharmaceutical Research Transparency Act of 2023

This bill requires the disclosure of costs associated with clinical trials and pharmaceutical research and development.

Specifically, the National Institutes of Health must create a publicly available repository of cost data from certain clinical trials that test the efficacy of drugs, biological products, and devices in human subjects. For each applicable trial, the registry must, among other information, include the total and per patient cost of the trial, as well as costs for personnel, health care services, and other categories of expenditures. Information must be added to the registry within one year of the trial's completion.

The bill also requires drug manufacturers to include their research and development expenditures for drugs and biological products in annual disclosures made to the Securities and Exchange Commission.

Actions Timeline

- **May 12, 2023:** Referred to the Subcommittee on Health.
- **May 9, 2023:** Introduced in House
- **May 9, 2023:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.